Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyl nicotinate is the methyl ester of nicotinic acid (niacin). It acts as a peripheral vasodilator when administered topically, leading to increased local blood flow by vasodilation of dermal capillaries, typically resulting in cutaneous erythema. Its pharmacological effects are thought to be mediated by the local release of prostaglandins, which relax vascular smooth muscle. Upon skin penetration, it is hydrolyzed to nicotinic acid and methanol. Main uses are as a rubefacient in over-the-counter topical analgesics for the relief of muscle and joint pain, and as a skin-conditioning agent in cosmetics. It is approved for use as an ingredient in external analgesic drug products and as a flavoring agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylnicotinate.